Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.
Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity. Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta. We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.
Byrnes
V
V
Department of Gastroenterology, Beth Israel Deaconess Hospital, Harvard Medical School, Boston, MA, USA. vbyrnes@bidmc.harvard.edu
Afdhal
N
N
Challies
T
T
Greenstein
P E
PE
D000276:Adjuvants, Immunologic / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D001707:Biopsy, Needle; D056486:Chemical and Drug Induced Liver Injury; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D016899:Interferon-beta / Q000009:adverse effects* / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects; D008107:Liver Diseases / Q000188:drug therapy / Q000473:pathology*; D008111:Liver Function Tests; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology; D011241:Prednisone / Q000627:therapeutic use; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D011241:Prednisone